Key facts
- NeuroVirt’s last known valuation is $11.0M (Jan 2025).
- It has raised $2.1M; the latest was Grant ($700K) in Oct 2025.
- Notable investors include Innovate UK, Endless Frontier Labs, Texas Medical Center, Genesis Ventures (Greece), LifeArc — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for NeuroVirt
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroVirt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroVirt
Developer of an XR rehabilitation platform designed to support engaging therapy, precise compensation control, and accurate remote monitoring for improved clinical care. The company offers therapy tools, real-time motion tracking, and clinician-controlled compensation settings, enabling physical and occupational therapy providers to deliver personalized, data-driven rehabilitation.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 10
- Website
- neurovirt.io/
- Ownership
- Privately Held (backing)
NeuroVirt doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroVirt shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroVirt in its N-PORT filings yet. We sweep new filings monthly.